Agreement for Daratumumab Receives Antitrust Clearance

Agreement for Daratumumab Receives Antitrust Clearance

Company Announcement

  *Daratumumab license agreement with Janssen Biotech, Inc., one of the
    Janssen Pharmaceutical Companies of Johnson & Johnson, receives antitrust
    clearance
  *License agreement has now become effective
  *Issue of new Genmab shares to Johnson & Johnson Development Corporation
    pursuant to a subscription agreement is subject to formal approval of a
    private placement prospectus

COPENHAGEN, Denmark, Sept. 21, 2012 (GLOBE NEWSWIRE) -- Genmab A/S
(Copenhagen:GEN) announced today that the worldwide license agreement for
daratumumab with Janssen Biotech, Inc., one of the Janssen Pharmaceutical
Companies of Johnson & Johnson, has received antitrust clearance from the
Federal Trade Commission and the Antitrust Division of the Department of
Justice under the Hart-Scott-Rodino Act. This means that the license agreement
has now become effective. A private placement prospectus containing details of
the issue of new Genmab shares to Johnson & Johnson Development Corporation in
connection with the agreement has been prepared in accordance with the
applicable rules and regulations and filed with the Danish Financial
Supervisory Authority. Upon the agency's approval, the new Genmab shares will
be registered with the Danish Business Authority by way of a capital increase
in Genmab and subsequently admitted to official listing and trading on the
NASDAQ OMX Copenhagen A/S, after which the subscription agreement will be
considered effective. The license agreement with Janssen Biotech, Inc. was
first announced on August 30, 2012 (Company Announcements 20 and 21).

About daratumumab

Daratumumab is a human CD38 monoclonal antibody with broad-spectrum killing
activity. Daratumumab is in clinical development for multiple myeloma (MM).
Daratumumab targets the CD38 molecule which is highly expressed on the surface
of multiple myeloma cells. Daratumumab could also have potential in other
cancers on which CD38 is expressed, including diffuse large B-cell lymphoma,
chronic lymphocytic leukemia, acute lymphoblastic leukemia, plasma cell
leukemia, acute myeloid leukemia, follicular lymphoma and mantle cell
lymphoma.

About Genmab A/S

Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future
product candidates. Partnering of innovative product candidates and
technologies is a key focus of Genmab's strategy and the company has alliances
with top tier pharmaceutical and biotechnology companies. For more
information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
"believe," "expect," "anticipate," "intend" and "plan" and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to
the outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment
in relation to our business area and markets, our inability to attract and
retain suitably qualified personnel, the unenforceability or lack of
protection of our patents and proprietary rights, our relationships with
affiliated entities, changes and developments in technology which may render
our products obsolete, and other factors. For a further discussion of these
risks, please refer to the risk management sections in Genmab's most recent
financial reports, which are available on www.genmab.com. Genmab does not
undertake any obligation to update or revise forward looking statements in
this Company Announcement nor to confirm such statements in relation to actual
results, unless required by law.

Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r);
HuMax(r)-EGFr; HuMax(r)-IL8; HuMax(r)-TAC; HuMax(r)-CD38; HuMax(r)-TF;
HuMax(r)-TF-ADC; HuMax(r)-Her2; HuMax(r)-cMet, HuMax(r)-CD74, DuoBody(tm)and
UniBody(r) are all trademarks of Genmab A/S. Arzerra(r) is a trademark of
GlaxoSmithKline.

Company Announcement no. 22
CVR no. 2102 3884

Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark